Recent developments in mRNA vaccines have shown promising results in terms of cost-effectiveness and effectiveness. Despite initial funding from President Donald Trump’s administration for mRNA vaccine development during the COVID-19 pandemic, there have been criticisms from the current administration. Trump recently canceled a substantial contract with Moderna for developing an mRNA vaccine targeting various flu strains, citing concerns about safety and testing. Health and Human Services Secretary Robert F. Kennedy Jr. also expressed doubts about the technology’s safety, labeling it as ‘under-tested.’ These conflicting views highlight the ongoing debate surrounding mRNA vaccines and their potential impact on public health.
Read more about this — here
